According to the research report titled ‘Global Inflammatory Bowel Disease (IBD) Market - Analysis By Disease Indication (Crohn's Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)’, available with Market Study Report, global inflammatory bowel disease (IBD) market was valued USD 210.5 billion in 2020 and is expected to register a healthy growth rate over the forecast period 2021-2026.
 

As per the report findings, rising prevalence of chronic diseases such as ulcerative colitis and Crohn’s disease, increasing government support for research activities, and advancements in medical technology are fueling global inflammatory bowel disease (IBD) market growth.  
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3733205/
 

Further, increased risk of bowel-related diseases owing to spike in cigarette smoking and alcohol consumption, alarming rise in pollution, and unhealthy lifestyles are adding to the market progression. Apart from these, expanding elderly population base, escalating healthcare expenditure, and growing investments in development of a robust pipeline for IBD are enhancing the industry outlook.
 

Global inflammatory bowel disease (IBD) market, based on disease indication, is split into Crohn’s disease and ulcerative colitis. With respect to drug class, the industry is fragmented into aminosalicylates, TNF inhibitors, integrin antagonists, and others. Moving on, the distribution channel segmentation comprises retail pharmacies, hospital pharmacies, and online pharmacies.
 

Considering the geographical landscape, major growth hubs for global inflammatory bowel disease (IBD) industry are North America (United States, Canada), Europe (France, Italy, Germany, Spain, United Kingdom), and Asia Pacific (China, India, Japan).
 

North America holds a coveted position in the market, attributable to rising burden of IBD, growing number of cigarette smokers in the U.S., and positive outlook of the R&D funding scenery in Canada. Moreover, strong presence of pharmaceutical and biosciences companies will continue to support the regional market growth in the upcoming years.
 

Leading players in global inflammatory bowel disease (IBD) market sphere are Eli Lilly & Company, UCB S.A., Novartis AG, GlaxoSmithKline plc, Celgene Corp., Roche Holding AG, Pfizer Inc., Takeda Pharmaceuticals Ltd., AbbVie Inc., and Johnson & Johnson.